胰腺酶替代治疗在慢性胰腺炎中的疗效:系统综述与Meta分析
该系统综述与Meta分析检索1966至2015年主要数据库,纳入17项随机对照试验(511例慢性胰腺炎患者),从14项研究合成定量数据。胰腺酶替代治疗(PERT)较基线和安慰剂均改善脂肪吸收系数,并减少粪便脂肪排泄、粪便氮排泄、粪便重量和腹痛,未报告显著不良事件。作者认为PERT用于纠正慢性胰腺炎外分泌胰腺功能不全和营养不良,更高剂量、肠溶包衣、随餐给药和抑酸可能改善疗效,需进一步研究确定最佳方案。
要点
- PERT较基线改善脂肪吸收系数(83.7±6.0 vs 63.1±15.0,p<0.00001;I²=89%)。
- PERT较安慰剂改善脂肪吸收系数(83.2±5.5 vs 67.4±7.0,p=0.0001;I²=86%)。
- PERT减少粪便脂肪排泄、粪便氮排泄、粪便重量和腹痛,未报告显著不良事件。
核心结论
- PERT适用于纠正慢性胰腺炎中的外分泌胰腺功能不全和营养不良,更高剂量、肠溶包衣、随餐给药和抑酸可能改善疗效。
- 需进一步研究确定最佳方案、健康不平等的影响及对营养的长期效应。
研究设计与样本
- 系统综述与Meta分析,检索1966至2015年主要数据库的随机对照试验。
- 共纳入17项研究(511例慢性胰腺炎患者)进行定性评估(Jadad评分),从14项研究合成定量数据。
- 主要结局为脂肪吸收系数。
主要发现
- PERT较基线改善脂肪吸收系数(83.7±6.0 vs 63.1±15.0,p<0.00001;I²=89%)。
- PERT较安慰剂改善脂肪吸收系数(83.2±5.5 vs 67.4±7.0,p=0.0001;I²=86%)。
- PERT改善氮吸收系数、减少粪便脂肪排泄、粪便氮排泄、粪便重量和腹痛,未报告显著不良事件。
- 随访研究显示PERT提高血清营养指标、改善胃肠道症状和生活质量,未报告显著不良事件。
- 高剂量或肠溶包衣酶制剂分别较低剂量或非包衣对照显示更大疗效的趋势。
关键数值与推荐
- 亚组、敏感性和Meta回归分析显示样本量、慢性胰腺炎诊断标准、研究设计和酶剂量导致异质性;缺乏健康不平等数据。
临床怎么用
- PERT适用于纠正慢性胰腺炎中的外分泌胰腺功能不全和营养不良。
- 更高剂量、肠溶包衣、随餐给药和抑酸可能改善疗效。
- 最佳方案、健康不平等的影响及长期营养效应尚需进一步研究确定。
局限性
- 样本量、慢性胰腺炎诊断标准、研究设计和酶剂量导致异质性。
- 缺乏健康不平等数据。
- 需进一步研究确定最佳方案、健康不平等的影响及对营养的长期效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The benefits of pancreatic enzyme replacement therapy (PERT) in chronic pancreatitis (CP) are inadequately defined. We have undertaken a systematic review and meta-analysis of randomised controlled trials of PERT to determine the efficacy of PERT in exocrine pancreatic insufficiency (EPI) from CP. DESIGN: Major databases were searched from 1966 to 2015 inclusive. The primary outcome was coefficient of fat absorption (CFA). Effects of PERT versus baseline and versus placebo, and of different doses, formulations and schedules were determined. RESULTS: A total of 17 studies (511 patients with CP) were included and assessed qualitatively (Jadad score). Quantitative data were synthesised from 14 studies. PERT improved CFA compared with baseline (83.7±6.0 vs 63.1±15.0, p<0.00001; I2=89%) and placebo (83.2±5.5 vs 67.4±7.0, p=0.0001; I2=86%). PERT improved coefficient of nitrogen absorption, reduced faecal fat excretion, faecal nitrogen excretion, faecal weight and abdominal pain, without significant adverse events. Follow-up studies demonstrated that PERT increased serum nutritional parameters, improved GI symptoms and quality of life without significant adverse events. High-dose or enteric-coated enzymes showed a trend to greater effectiveness than low-dose or non-coated comparisons, respectively. Subgroup, sensitive and meta-regression analyses revealed that sample size, CP diagnostic criteria, study design and enzyme dose contributed to heterogeneity; data on health inequalities were lacking. CONCLUSIONS: PERT is indicated to correct EPI and malnutrition in CP and may be improved by higher doses, enteric coating, administration during food and acid suppression. Further studies are required to determine optimal regimens, the impact of health inequalities and long-term effects on nutrition.
引用
- de la Iglesia-García D, Huang W, Szatmary P, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. Gut. 2016. PMID: 27941156. doi:10.1136/gutjnl-2016-312529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。